Bristol Myers Squibb Company $BMY Holdings Lifted by Czech National Bank

Czech National Bank increased its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 3.8% in the 4th quarter, Holdings Channel reports. The fund owned 536,798 shares of the biopharmaceutical company’s stock after purchasing an additional 19,839 shares during the period. Czech National Bank’s holdings in Bristol Myers Squibb were worth $28,955,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Darwin Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the second quarter worth approximately $25,000. Harbor Capital Advisors Inc. increased its stake in Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 313 shares during the period. Beacon Financial Strategies CORP purchased a new stake in Bristol Myers Squibb in the 4th quarter worth approximately $38,000. KERR FINANCIAL PLANNING Corp acquired a new stake in shares of Bristol Myers Squibb during the 3rd quarter valued at $35,000. Finally, JPL Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at $36,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

BMY has been the subject of several recent research reports. HSBC increased their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a “hold” rating in a report on Tuesday, March 17th. Guggenheim reaffirmed a “buy” rating and set a $72.00 price target (up from $62.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. The Goldman Sachs Group reissued a “neutral” rating and issued a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Morgan Stanley reaffirmed an “underweight” rating and set a $40.00 price objective on shares of Bristol Myers Squibb in a research report on Friday, February 6th. Finally, Leerink Partners boosted their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Nine equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY opened at $58.94 on Thursday. The business’s 50-day simple moving average is $58.69 and its 200-day simple moving average is $52.06. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $62.89. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26. The firm has a market cap of $120.02 billion, a price-to-earnings ratio of 17.08, a P/E/G ratio of 0.16 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the business earned $1.67 EPS. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.